The trading price of Kintara Therapeutics Inc (NASDAQ:KTRA) closed lower on Monday, April 22, closing at $0.11, -5.85% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $5.98 and a 52-week low of $0.08. Over the past month, the stock has gained 24.92% in value.
Kintara Therapeutics Inc, whose market valuation is $6.32 million at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $0 per share this quarter, however they have predicted annual earnings per share of -$0.46 for 2024 and -$0.38 for 2025. It means analysts are expecting annual earnings per share growth of 95.00% this year and 17.40% next year.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Kintara Therapeutics Inc no upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest KTRA has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
A quick review shows that KTRA’s price is currently -0.29% off the SMA20 and 7.82% off the SMA50. The RSI metric on the 14-day chart is currently showing 50.21, and weekly volatility stands at 8.08%. When measured over the past 30 days, the indicator reaches 13.20%. Kintara Therapeutics Inc (NASDAQ:KTRA)’s beta value is currently sitting at 0.49, while the Average True Range indicator is currently displaying 0.02.
To see how Kintara Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: KTRA stock’s performance was -5.85% in the latest trading, and -96.53% in the past year.
An evaluation of the daily trading volume of Kintara Therapeutics Inc (NASDAQ:KTRA) indicates that the 3-month average is 13.85 million.
Currently, records show that 55.30 million of the company’s shares remain outstanding. The insiders hold 0.19% of outstanding shares, whereas institutions hold 0.40%. However, since the stock’s price has seen -32.61% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
